Clinical Trial

Sirolimus Use in Angioplasty for Vascular Access Extension

Study Description

Sirolimus Use in Angioplasty for Vascular Access Extension

Dialysis patients presenting for angioplasty intervention for graft failure will be randomized to receive either Sirolimus or not receive Sirolimus (standard of care) to assess the time from primary failure or angioplasty intervention to second or next angioplasty intervention or graft failure.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Drug - Sirolimus

3 mg po od loading dose for two days, then 2 mg po od for thirty days

Additional Information

Official Study Title

A Randomized Open Label Trial of Oral Sirolimus for Decrease of Stenosis in Arteriovenous Fistula in Hemo-dialysis Patients When Compared With Standard Therapy

Clinical Trial ID

NCT01595841

ParticipAid ID

mbk8xd